Artelo Biosciences, Inc.

NasdaqCM ARTL

Artelo Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023

Artelo Biosciences, Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2023. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Artelo Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 19.48 M, a 93.57% change year over year.
Artelo Biosciences, Inc. Cash and Short-Term Investments for the quarter ending August 31, 2021 was USD 10.06 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: ARTL

Artelo Biosciences, Inc.

CEO	Mr. Gregory D. Gorgas M.B.A.
IPO Date	June 21, 2019
Location	United States
Headquarters	505 Lomas Santa Fe
Employees	5
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Mental Health Pet Food Pharmaceuticals Vaccines

Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Key trends

Past 5 years